[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631780":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":26,"responsibleParty":31,"collaborators":35,"id":39,"slug":26,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":26,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":26,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":26,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":26},{"fullName":5,"class":6},"Penn State University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Food advertisement group","EXPERIMENTAL","Advertisements viewed daily by this group will be food and\u002For beverage products",[13],"Behavioral: Food advertisements",{"label":15,"type":16,"description":17,"interventionNames":18},"Tech advertisement group","PLACEBO_COMPARATOR","Individuals in this group will only receive tech-related advertisements daily",[19],"Behavioral: Tech advertisements",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Food advertisements","Videos and images of food and beverage advertisements from popular brands and\u002For restaurants",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Tech advertisements","Video and photo advertisements of popular tech tools",[15],{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Travis Masterson","Assistant Professor and Director of the Health, Ingestive Behavior, and Technology Lab",[36],{"name":37,"class":38},"Penn State Health","UNKNOWN","100631780",false,"NCT07505134","Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements","Exploring the Influence of GLP-1 Medications on External Food Cue Reactivity and Resultant Food Choice and Intake","Inclusion Criteria:\n\n* Adults (18+) with overweight or obesity (BMI \\>25 kg\u002Fm2)\n* On an injectable form of tirzepatide GLP-1 medication at a minimum dose of 7.5 mg, taking it as prescribed by their doctor\n* Not currently taking an incretin-based medication at baseline other than the GLP-1 medication\n* Fluent in English\n\nExclusion Criteria:\n\n* Do not have consistent access to a smart phone that can access the study software\n* Diagnosed with cognitive or physical disability or epilepsy\n* Adults taking a compound GLP-1","ALL","18 Years","85 Years",{"count":49,"type":50},50,"ESTIMATED","INTERVENTIONAL",[53],"NA","The purpose of this randomized control trial is to compare how food cravings, food selection, and food consumption change in response to frequent food advertisements compared to non-food advertisements in adults taking GLP-1 (weight loss) medications. The primary question we aim to answer is: do GLP-1 medications reduce an individual's vulnerability to external triggers that drive food cravings and consumption?\n\nParticipants will:\n\n* report daily food consumption for a total of 10 days,\n* receive eight daily prompts to view food or non-food related advertisements, and respond to a short 9-question survey for 7 days,\n* answer several questionnaires,\n* and complete two in-person visits to complete a virtual reality food selection task.",[56],"GLP - 1",[58,59,60,61],"GLP-1","Food choice","Cravings","Food cue reactivity","NOT_YET_RECRUITING","2026-04-27",{"date":65,"type":66},"2026-05-01","ACTUAL",{"date":68,"type":50},"2026-05",{"date":70,"type":50},"2026-09",{"name":5,"class":6}]